Intratumoral Therapy to Make a ?Cold? Tumor ?Hot?: The Jury Is Still Out

Tilsotolimod, an oligodeoxynucleotide TLR9 agonist, admin-istered intratumorally, has been clinically evaluated. This compound has demonstrated the ability to induce changes within the tumor microenvironment, to convert noninflamed cold tumors into inflamed hot tumors, with the hope that these tumors will be more responsive to immune checkpoint blockade.See related article by Babiker et al., p. 5079

Automated summary

Tilsotolimod, a TLR9 agonist, administered intratumorally, has the ability to change the tumor microenvironment, converting noninflamed tumors into inflamed ones and potentially increasing their responsiveness to immune checkpoint blockade.